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Abstract
Palliative care is an approach that improves quality of life for patients and their families facing problems associated with a life-threatening
illness. Care planning is particularly important in CF, where predicting a time of death is extremely difﬁcult. The patient and family should re-
ceive realistic information about health status and further options of care. Particularly important is the explanation that treatment does not stop
during the terminal phase of the disease, instead the primary aim is to alleviate unpleasant symptoms. More invasive end of life care is becom-
ing the norm in patients awaiting lung transplantation. Terminal care should be organised in the place chosen by the patient and their family.
Ideally terminal care should not end when the patient dies, instead psychological and spiritual support should continue to bereaved families.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Background
People with cystic ﬁbrosis (CF) experience a slow de-
terioration of lung function coupled with numerous disease
complications which may continue for many years. This
long, chronic phase means that patients undergo an intensive
daily therapy regimen making it difﬁcult to predict prog-
nosis. Constant therapeutic demands, limited predictability
of the terminal phase and difﬁculty in deﬁning the point
that treatment ceases to be effective, reﬂect differences with
oncology where the decision to introduce alternative therapies
is well identiﬁed [1]. Given these time sequences a patient
with cancer, their family and clinicians may ﬁnd it easier to
accept and deal with death. The timing of death is difﬁcult
to predict in CF, therefore active and palliative treatment
usually continue at the same time, this may help to explain
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why most patients with CF die in hospital [2,3]. Different
family members are involved with providing or supporting
care throughout the various life stages of patients with CF,
these can be parents, siblings, partners or the children of
parents with CF. The term family used throughout refers to all
these people, acknowledging changes at different ages.
Although the majority of patients with CF die following
overwhelming pulmonary infection, technological advances
have provided the CF team with alternative treatment choices
for the very sick patient. Lung transplantation is a viable
option for patients with CF, although it must be acknowledged
that not all patients are suitable and organ availability remains
an issue [2]. The situation differs dramatically around Europe:
from countries without the option of lung transplantation, to
countries with long waiting lists and countries where lung
transplantation can be performed in weeks or even days
when urgent. When lung transplantation is chosen the CF
team, in partnership with the transplant team must provide
careful assessment and preparation as many patients initially
believe that transplantation is a cure and underestimate the
commitment necessary both before and after the operation [3].
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A number of CF Centres are re-evaluating the possibility
of intensive care, especially for those patients awaiting
lung transplantation. Both invasive mechanical ventilation
(IMV) and non-invasive ventilation (NIV) are choices that
must be considered whenever appropriate [4,5]. Even though
the mortality rate for patients undergoing IMV remains
high, recent research reports some improvement, particularly
for transplanted patients [6–9]. Although these data are
insufﬁcient to be able to derive ﬁrm conclusions, it is clear
that where suitable, these options should be proposed and
discussed with the patient and family.
In summary, the characteristics of the end of life phase in
CF include:
• Difﬁculty in establishing a terminal phase
• A reluctance in some instances to introduce palliative care
• Active treatment continued until the time of death
• Possible lung transplantation
• The possible use of invasive or non-invasive mechanical
ventilation
It is clear that CF teams need to agree end of life care poli-
cies for their individual patient populations. Although many
CF Centres routinely offer symptom control and palliative
care concurrent with active treatment, there still remains a
number of places where this does not happen. Palliative care
should be given a wider deﬁnition and considered not only
as an option for terminally ill patients but as being similar to
all therapies (pharmacological or not) where relief from pain
and other distressing symptoms is provided. Thus, palliative
care can be automatically integrated with ongoing therapies
at every stage of the disease. The control of symptoms does
not interfere with the strategy of clinical improvement, but is
an objective in and of itself. This deﬁnition makes the role
of palliation in chronic disease very different from the usual
cures of the last days of life. The acceptance of a wider use of
palliative care (pharmacological, psychological and spiritual)
can for example allow the treatment of chronic pain, nausea,
anxiety and dyspnoea, which may be ignored in these patients
even during the terminal stages.
Treating the symptom of pain also involves the psycholog-
ical and spiritual aspects of palliation and has been deﬁned
by the World Health Organisation (WHO) [10] for both adults
and children.
“Palliative care is an approach that improves the quality of
life of patients and their families facing problems associated
with a life-threatening illness. This is provided through the
prevention and relief of suffering by means of early identiﬁ-
cation, accurate assessment and treatment of pain and other
problems, physical, psychosocial and spiritual. Palliative care:
• Provides relief from pain and other distressing symptoms
• Afﬁrms life and regards dying as a normal process
• Intends neither to hasten nor to postpone death
• Integrates the psychological and spiritual aspects of patient
care
• Offers a support system to help patients live as actively as
possible until death
• Offers a support system to help the family cope during the
patient’s illness and in their own bereavement
• Uses a team approach to address the needs of patients
and their families, including bereavement counselling, if
indicated
• Will enhance quality of life, and may also positively
inﬂuence the course of illness
• Is applicable early in the course of illness, in conjunction
with other therapies that are intended to prolong life, such
as chemotherapy or radiation therapy, and includes those
investigations needed to better understand and manage
distressing clinical complications.”
“Palliative care for children represents a special, albeit
closely related ﬁeld to adult palliative care. The WHO’s
deﬁnition of palliative care appropriate for children and their
families is as follows; the principles apply to other paediatric
chronic disorders [10]:
• Palliative care for children is the active total care of the
child’s body, mind and spirit, and also involves giving
support to the family
• It begins when illness is diagnosed, and continues regard-
less of whether or not a child receives treatment directed at
the disease
• Health providers must evaluate and alleviate a child’s
physical, psychological, and social distress
• Effective palliative care requires a broad multidisciplinary
approach that includes the family and makes use of
available community resources; it can be successfully
implemented even if resources are limited
• It can be provided in tertiary care facilities, in community
health centres and even in children’s homes.”
2. Care planning
Planning is essential and should occur early in the course
of the illness. The care team should be open, honest, and
sensitive to family and cultural issues. Care planning is a
process of structured discussion and documentation woven
into the regular process of care. The goal is to ensure that a
patient and their family’s wishes will be respected [11].
Care planning is particularly important in CF, where
predicting a time of death is extremely difﬁcult [12]. The
terminal phase of the disease is usually heralded by an in-
creased frequency and severity of exacerbations, dependence
on oxygen therapy, a relentless deterioration in pulmonary
function and increased pain in some patients. The patient
and family should receive realistic information about health
status and further options of care. Particularly important is the
explanation that treatment does not stop during the terminal
phase of the disease, instead the primary aim will be to allevi-
ate unpleasant symptoms [13]. The wishes of both the patient
and their family concerning treatment options and place of
death should always be respected and supported whenever
possible. Early management planning in the terminal phase of
the disease not only allows the patient and family to prepare
for the moment of death, but also provides time for important
decisions to be made such as putting affairs in order and
planning a funeral. End of life care should be considered in
patients who do not agree to further treatment and are in the
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terminal stages of the disease, or who do not fulﬁl the criteria
for lung transplantation or who do not wish to undergo lung
transplantation. It is important to remember that patients who
are on the lung transplant waiting list should not be excluded
from palliative care options.
3. Therapy
3.1. Palliative care
The main symptoms requiring medical management in the
terminal phase of the disease are dyspnoea, nausea, pain, anx-
iety, and confusion. The terminal phase of pulmonary disease
still requires oxygen therapy, nebulised medication and phys-
iotherapy. Often patients display symptoms of breathlessness
and can become distressed, both NIV and benzodiazepines or
antidepressants can be helpful in these instances. One of the
more common drugs used in terminal dyspnoea is morphine
and its derivates [14]. These can be administered via a variety
of routes suitable to patient needs including oral, transder-
mal, sublingual and intravenous. Occasionally morphine can
be nebulised; however the effectiveness of drug absorption
varies between patients. Retrospective studies have shown that
patients can tolerate levels of opiate sufﬁcient to manage dys-
pnoea without respiratory depression. Intravenous morphine
of less than 5 mg per hour has been reported to control
dyspnoea in the majority of patients with CF [15–17]. Opiate
medication (opioids) may be combined with benzodiazepines,
antidepressants, anxiolytics and antiemetics. The combination
of drugs should be adjusted to the individual needs of the
patient (Table 1). Palliative sedation is the monitored use of
medications to relieve refractory and unendurable symptoms,
by inducing varied degrees of unconsciousness. The intent of
palliative sedation is control of suffering, not to hasten death
(Table 2) [18].
In the ﬁnal phase of the disease it is uncommon to intubate
and ventilate individuals; however NIV is common for
symptom relief and as an aid to chest physiotherapy. Before
commencing this form of therapy counselling is important for
both the patient and their family as they need to understand
that NIV is not being used to prolong the process of dying,
Table 1
Treatment for dyspnoea
Morphine (short acting)
• Suggested starting dose: children 0.15–0.3 mg/kg, adolescents and adults
2.5–5 mg every 4 hours PO
• End of life period – Infusion IV or SQ dose should be 33–50% of the
oral dose
• Drug may be mixed with benzodiazepines, antidepressants and hyoscine.
• Inhalations: 2.5–5 mg/dose
Hyoscine
• Suggested starting dose 10 mg q 8–12 h PO or 7.5–10 mg q 5–12 h PR
and then 20–40 mg/24 h infusion IV or SQ
Note: These treatment options and doses are provided as a guide only, most
hospitals will have their own protocols which should be followed.
Abbreviations: IV, intravenous; SQ, subcutaneous; PO, per os; PR, per
rectum.
but to help with symptoms such as breathlessness and to clear
secretions from the lungs. In the terminal phase of the disease
psychological, spiritual and social support is mandatory.
3.2. Lung transplantation
With the wider adoption of lung transplantation as a rescue
therapy for end stage CF lung disease, end of life care for CF
has changed [19]. For patients on the lung transplant list, the
goal is to keep the patient as well as possible until potential
donor organs can be found. Given this goal, more aggressive
interventions such as NIV or IMV, intensive care, enteral
feeding, and indwelling catheters, are appropriate [11,20,21].
3.2.1. Prediction of short-term mortality
A signiﬁcant difﬁculty in end of life care for patients
with CF is the inability to predict short-term survival with
accuracy. Short-term prognostic ability is limited both by
the relatively high degree of inter-patient variability and the
natural course of the pulmonary decline. Some attempts to
develop prognostic markers for mortality in CF have initially
focused on pulmonary function testing [12,22–24]. These
studies are motivated by the need to provide an appropriate
time for lung transplant listing given the waiting time for
suitable organs. As a consequence, they usually focus on
prediction of mortality within a two year period and are of
limited use in making plans for end of life care.
Other studies have focused on clinical signs of advancing
disease and other useful clinical indicators of poor short-term
survival. These include the inability to maintain metabolic
compensation for chronic respiratory acidosis, presence of
pulmonary hypertension, an accelerated rate of decline in
pulmonary function despite aggressive therapy, the lack of
response to prolonged intravenous antibiotic therapy, and
weight loss that cannot be halted or reversed by supplemental
feeding or parenteral nutrition [25–28]. Despite the lack of
convincing evidence on prognosis, prediction of the appropri-
ate time to offer lung transplantation to CF patients remains
largely subjective. This concept is reinforced in a recent
update of guidelines for the selection of candidates for lung
transplantation where the authors have reported that decision
making will be supported by several indicators of disease
severity. These indicators include: FEV1, increased oxygen
need, hypercapnia, the need for non-invasive ventilation,
functional status (e.g. six minute walk test), and pulmonary
hypertension [28–30] (Tables 3 and 4).
3.2.2. Impact of lung transplantation on end-of-life care
Two single centre studies have focused speciﬁcally on the
effect of lung transplantation on end of life care. In the study
by Dellon et al. [31] patients on the lung transplantation
waiting list were more likely to die in the intensive care
unit (ICU), more likely to remain intubated on the last
day of life, and more likely to have the discussion about
terminal care delayed. This meant that patients were unable
to participate in any decision making plans. A similar
study by Ford and Flume [19] found that patients on
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Table 3
Clinical risk factors for death in CF patients [28,29]
Patients with CF not listed for transplant
• Pulmonary function and exercise capacity
• Microbiology (e.g. Pseudomonas aeruginosa, Staphylococcus aureus,
Burkholderia cepacia complex)
• Nutritional status (weight)
• Age
• Female sex
• Pancreatic insufﬁciency
• CF-related diabetes
• Lower socioeconomic status
• Pulmonary hypertension
• Number of acute exacerbations
• Geographic location
• CF centre care
Patients with CF listed for transplant
• Yearly rate of decline in percent predicted FEV1
• Exercise test results (distance, SaO2)
• Pulmonary hypertension
• CF-related diabetes
• Nutritional status/intervention
• PCO2 and PO2
Table 4
Guideline for referral and listing for lung transplantation [30]
Guidelines for referral
• FEV1 below 30% predicted or a rapid decline in FEV1 (particularly in
young female patients)
• Exacerbation of pulmonary disease requiring ICU admission
• Increasing frequency of exacerbations requiring antibiotic therapy
• Refractory and/or recurrent pneumothorax
• Recurrent haemoptysis not controlled by embolisation
Guidelines for transplantation
• Oxygen-dependent respiratory failure
• Hypercapnia
• Pulmonary hypertension
the lung transplantation waiting list were more likely to
die in the ICU receiving assisted ventilation. Ford and
Flume [19] argue that the provision of more aggressive care
to those awaiting lung transplantation is appropriate and
surmise that clinicians are opting for aggressive care without
considering the realistic odds of survival to transplantation.
There are however differing management styles around the
world with many adult CF centres in both the UK and Europe
successfully using NIV without the need to transfer patients
to an ICU. This practice has the advantage of keeping patients
involved in their treatment decisions and end of life planning
right up until the last day of life.
There appears to be reluctance on the part of CF clinicians
to discuss advanced care planning, even though adults with
CF may wish to do so. In a national survey of 234 adults
with CF, 79% reported feeling comfortable talking to their
clinician about advanced directives or advanced care planning,
but only 28% said that their CF clinicians had asked about
these issues [11]. A more comprehensive understanding of
the factors that promote or hinder effective decision-making
about lung transplantation and a more detailed directive on the
use of medical interventions as death approaches should help
clinicians support patients and families through this complex
set of decisions.
3.2.3. Management of advanced lung disease prior to
transplantation
Patients with CF should be cared for by a multidisciplinary
team in a specialist CF centre. Treatment options for pa-
tients with advanced lung disease should be maximised by
optimising all relevant aspects of care, for example, airway
clearance techniques should be adapted to the patient’s needs
and circumstances and aerobic exercise should be performed,
whenever possible. Nebulised rhDNAse can be used even
in severely ill patients and nebulised hypertonic saline may
have additional beneﬁts. In patients infected by Pseudomonas
aeruginosa (PA), maintenance inhaled antibiotics are standard
care, although treatment options include monthly or alternate
monthly nebulisers often with two different antibiotics. Acute
exacerbation of chronic bacterial infections should be treated
promptly with at least two different antimicrobial agents. In
very sick patients with CF, the optimal duration of treatment is
unknown, but might well be beyond the empirical 14–21 days.
Respiratory complications, such as pneumothorax and mas-
sive haemoptysis need adequate intervention and may prompt
consideration for lung transplantation [20]. There are no data
supporting steroid use in end stage CF. However, steroids
have been found to be helpful particularly in patients with
an element of small airways disease. In patients with weight
loss or low BMI, nutritional supplements should be offered.
CF related diabetes (CFRD) should be always excluded, if
found, vigorous insulin treatment with continuous glucose
monitoring should be introduced according to guidelines [32].
3.2.4. Management of respiratory failure
When end-stage CF lung disease leads to hypoxemic
and/or hypercapnic respiratory failure, long-term oxygen
therapy with or without assisted ventilation may become
necessary. As there are no speciﬁc guidelines for the use
of long-term oxygen supplementation therapy [21] and non-
invasive ventilation (NIV) in patients with CF, published
guidelines for other chronic obstructive lung diseases may be
considered [33].
A French survey on the use of NIV in 4,416 patients
with CF showed that it is used as a ﬁrst-line treatment for
severe hypercapnic respiratory exacerbation and for stable
diurnal hypercapnia, especially when associated with sleep
disturbances. Bi-level, pressure-targeted ventilation is a sug-
gested ventilation mode. Settings are adjusted to arterial blood
gas values, patient comfort and sometimes sleep studies. The
surveyed centres reported a number of expected beneﬁts from
NIV, but few of those beneﬁts have been formally proven
[34]. Long-term NIV with biphasic positive airway pressure
(BiPAP) or intermittent nasal positive pressure may also fea-
ture as a “bridge” to transplantation [35]. In other patients,
these techniques can be used in the short term as a moder-
ately effective therapy for dyspnoea or to facilitate sputum
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expectoration during physiotherapy. However, they require a
period of adaptation and it must be remembered that there is
a point at which NIV fails to control hypercapnia. It could be
argued that the use of NIV may complicate end-of-life care
and may appear for some patients to be only marginally less
“invasive” than endotracheal intubation. However, patients
using NIV, particularly older children and adults, are able
to communicate about the helpfulness or otherwise of this
treatment thereby being involved in decisions about whether
to continue or stop at any time.
The use of IMV at the end of life is increasing in
CF and it appears that the consensus against the use of
aggressive care at the end of life in CF may be eroding.
Prior to the widespread availability of lung transplantation,
placing an older patient with CF on IMV was considered
to be futile because it could not reverse the underlying lung
disease and was associated with high mortality rates. Neither
physicians nor patients wanted the patient to be transferred
to the ICU if death on the ventilator was the likely outcome.
Early studies demonstrated that survival in adults requiring
intubation and IMV due to acute respiratory failure did not
improve [36]. Recently, in the context of improved overall
survival and the availability of lung transplantation, several
studies have reassessed indications for intensive care and
IMV in CF. Patients with acute respiratory failure due to
an acute reversible condition (haemoptysis, pneumothorax or
antibiotic allergy) have been reported as having a one year
survival indicating that ICU treatment, including IMV, may be
both appropriate and effective for those patients [4,6,37,38].
Survival among patients with acute-on-chronic respiratory
failure without any identiﬁable triggering event necessitating
IMV is less effective, but in a study by Sood et al. [4] 55%
survived to ICU discharge; 40% received lung transplants and
33% were alive one year later. Intensive care, including IMV,
might also be appropriate in the selected CF lung transplant
candidate as a bridge to lung transplantation. The likelihood
that a patient will be transplanted in due time should however,
be considered when deciding to proceed with this strategy, as
waiting times will vary in different countries. Several groups
have reported similar transplant outcomes in ventilated CF
patients compared with non-ventilated candidates [5].
Despite these promising results, clinicians and patients
should carefully consider the decision to use non-invasive
or invasive ventilation, as end of life care for patients with
CF may be made more difﬁcult in the ICU setting, in that
the withdrawal of ventilatory support will be the common
mode of death. In a sense, these methods may introduce
an unsettling sort of “choice” into the decisions surrounding
terminal care. Many patients with CF have grown up with a
certain image of how their last weeks and days will be spent,
and the introduction of an alternative is likely to challenge the
expectations of both patients and caregivers.
4. Psychological aspects
End of life care in CF is very different to models used in
other disease specialties such as oncology. In CF, palliative
care is introduced in parallel to active treatment as both
therapeutic models help to improve and relieve symptoms. Pa-
tients and families need support and involvement in treatment
decision making at this time as it can be confusing. Many
families and patients may have little or no experience of death
or of being with someone at the end of life and can feel fright-
ened by the unknown, therefore constant explanation must
be provided. In addition, CF teams must keep in mind that
both parents or partners will have been actively involved in
providing care for many years and may need encouragement
to continue, both for themselves and for their loved one.
It is necessary to remember the following points:
• Good communication between the CF team, the patient and
their family is paramount during all aspects of the terminal
stages. The CF team must take into account the patient
and their family’s level of understanding, concern, and fear
of the unknown when discussing any treatment changes
and be prepared to answer questions and re-discuss issues
throughout this time [13].
• Treatment choices must allow for continued good commu-
nication between the patient and his/her family.
• It is important to provide support to friends and family
about the issue of visiting and staying with the patient.
• It is important for the CF team to understand the possibil-
ities and limitations of the care they are able to provide
[39].
• The CF team, the patient and the family must work in
partnership when planning end of life care, including
providing comfort and the use of analgesia and anxiolytics.
• Bereavement support for friends and family often starts
before death and continues afterwards. Provision should be
made for support to be offered whenever necessary [40].
Attention to all these points can assist in creating a
communication pathway with the patient and their family so
that their needs can be met fully. Families who have been
bereaved will continue to struggle with their loss. However,
if they feel that they were fully involved in the process and
received ongoing and appropriate support and understanding,
then the bereavement process can become easier.
5. Organisation of terminal care
Terminal care should be organised in the place chosen by
the patient and their family (hospital, hospice where possible,
or home). Whatever option is chosen it should not restrict
cooperation between the CF team and palliative care team
(doctor, nurse, physiotherapist, psychologist, social worker,
member of the multi-faith chaplaincy).
Ideally terminal care should not end when the patient dies,
instead psychological and spiritual support should continue to
the bereaved families. There are many methods to provide this
service and families should be offered one that meets their
needs, these include individual or group counselling provided
by the CF Centre, individual or group counselling provided by
the family doctor or individual or group counselling provided
by associated agencies.
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6. Conclusion
Although therapeutic innovations may continue to enhance
survival and quality of life, families, patients, and physicians
will still have to confront the premature mortality that
accompanies the essentially fatal diagnosis of CF. Even in a
period of advancing survival, compassionate and skilful end
of life care will remain an essential part of comprehensive
care for patients and their families, requiring specialist skills
and good cooperation of the CF and palliative care teams.
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